Blog

MHRA-NICE aligned pathway

MHRA-NICE aligned pathway

The MHRA-NICE aligned pathway opens on 1st April 2026. The pathway and an improved advice service will help get new medicines to patients faster and support companies to plan with more certainty.

Pharmacy Consulting Ltd – Audit Training

Pharmacy Consulting Ltd – Audit Training

In today’s highly regulated pharmaceutical distribution landscape, the ability to audit effectively isn’t just a compliance requirement – it’s a defining characteristic of operational excellence. At the heart of every resilient quality system lies a structured, insightful, and well-executed audit process. That’s exactly where our Audit Training Package begins to distinguish itself.

RP Refresher Training

RP Refresher Training

In the world of pharmaceutical distribution, standing still is not an option. Regulations evolve, expectations sharpen, and the responsibility carried by Responsible Persons (RPs) continues to grow. Maintaining clarity, confidence, and compliance requires more than experience alone – it requires regular refinement.

RP Refresher Training

RP Refresher Training

The RP Refresher Training course is designed specifically for RPs and Deputy RPs as an annual refresher on the GDP guidelines plus additional areas applicable to RPs and their nominated deputies.

The MHRA’s Guide to Defective Medicinal Products – Part 2

The MHRA’s Guide to Defective Medicinal Products – Part 2

In the world of pharmaceutical distribution, product recalls aren’t an occasional inconvenience—they’re an operational reality. And when they occur, the expectations on wholesale dealers are high. The MHRA’s guidance is clear: distributors sit at a pivotal junction in the recall process, and their preparedness can determine whether a quality issue stays contained or becomes a national problem.

The MHRA’s Guide to Defective Medicinal Products – Part 1: Overview

The MHRA’s Guide to Defective Medicinal Products – Part 1: Overview

When quality issues arise in the lifecycle of a medicinal product, the consequences extend far beyond the pharmacy shelf. The MHRA’s latest 2026 guidance on defective medicinal products offers a comprehensive roadmap for managing these events with rigour, transparency, and patient safety at the centre.